A Retrospective, Multicenter Study to Evaluate the Impact of Pre-CAR Blinatumomab on Subsequent CD19 CAR Outcomes in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia (r/r ALL)
Latest Information Update: 12 Jan 2021
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary) ; Blinatumomab (Primary) ; Tisagenlecleucel (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.